NEW YORK, September 28, 2015 /PRNewswire/ --
ACI Association has initiated research coverage on the following
equities: Achillion Pharmaceuticals, Inc. (NASDAQ:
ACHN), Aratana Therapeutics, Inc. (NASDAQ: PETX), Akorn,
Inc. (NASDAQ: AKRX), EDAP TMS S.A. (NASDAQ: EDAP),
Fibrocell Science Inc. (NASDAQ: FCSC). On Friday, September 25, 2015, Nasdaq ended at
4,686.50 down 1.01%, Dow Jones advanced 0.70%, to finish the day at
16,314.67, and the S&P closed at 1,931.34, down 0.05%. Register
for your complimentary reports at the links given below.
--
Achillion Pharmaceuticals Inc.
--
Achillion Pharmaceuticals Inc.'s stock edged lower by 10.12% to
close Friday's session at USD 7.60.
The company's shares oscillated between USD
7.35 and USD 8.59. The stock recorded a trading volume of
3.47 million shares, which was above its 50-day daily average
volume of 2.66 million shares and below its 52-week average volume
of 4.53 million shares. Over the last three days, Achillion
Pharmaceuticals Inc.'s shares have declined by 10.65% and in the
past one week it has moved down 12.60%. Furthermore, over the last
three months, the stock has lost 12.60% and in the past six months,
the shares have shed 25.25%. The stock is trading at a price to
book ratio of 3.71, which compares to a historical PB ratio close
to 8.85. Sign up and read the free notes on ACHN at:
http://www.aciassociation.com/ACHN.pdf
--
Aratana Therapeutics Inc.
--
The stock of Aratana Therapeutics Inc. lost 38.99% to close
Friday's session at USD 10.67. The
shares of the company moved in the range of USD 10.52 and USD
16.35. A trading volume of 2.95 million shares was recorded,
which was greater than its 150-day daily average volume of 0.33
million shares and above its 52-week average volume of 0.30 million
shares. Over the last five days, Aratana Therapeutics Inc.'s shares
have declined by 45.92% and in the past one month, it has lost
38.78%. Additionally, over the last three months, the stock has
declined 20.61% and in the past six months, the shares have
registered a loss of 34.34%. Register for free on ACI Association
and access the latest research on PETX at:
http://www.aciassociation.com/PETX.pdf
--
Akorn Inc.
--
Akorn Inc.'s stock decreased by 9.28% to close Friday's session
at USD 32.06. The company's shares
fluctuated in the range of USD 31.51
and USD 35.35, marking a new 52-week
low during the session. A total of 1.81 million shares exchanged
hands, which surpassed its 50-day daily average volume of 0.98
million shares and was above its 52-week average volume of 1.65
million shares. Over the last three days Akorn Inc.'s shares have
declined by 14.16% and in the past one week it has moved down
17.69%. Furthermore, over the last three months, the stock has lost
26.32% and in the past six months, the shares have shed 33.87%.
Further, the stock is trading at a price to earnings ratio of 97.15
and a price to book ratio of 9.26. This compares to a historical PE
ratio of 106.94 and a historical PB ratio close to 10.46. The
complete research on AKRX is available for free at:
http://www.aciassociation.com/AKRX.pdf
--
Edap Tms SA
--
Edap Tms SA's stock added 8.65% to close Friday's session at
USD 5.65. The company's shares
oscillated between USD 5.20 and USD
5.80. The stock recorded a trading volume of 1.61 million
shares, which was above its 50-day daily average volume of 0.16
million shares and above its 52-week average volume of 0.18 million
shares. Over the last five days, Edap Tms SA's shares have advanced
16.02% and in the past one month, it has gained a momentum of
71.21%. In addition, over the last three months, the stock has
gained 67.66% and year to date, the shares have picked up 142.49%.
Further, the stock is trading at a price to earnings ratio of
71.97. Additionally, the stock is trading at a price to cash sales
ratio of 4.33. Free in-depth research on EDAP is available at:
http://www.aciassociation.com/EDAP.pdf
--
Fibrocell Science Inc.
--
Fibrocell Science Inc.'s stock declined 23.73% to close Friday's
session at USD 4.95. The share price
vacillated between USD 4.50 and USD
6.12. The stock recorded a trading volume of 1.19 million
shares, which was above its 50-day daily average volume of 0.33
million shares and above its 52-week average volume of 0.19 million
shares. Over the last three days Fibrocell Science Inc.'s shares
have declined by 18.45% and in the past one week it has moved down
25.23%. Moreover, in the last six months, the stock has gained
20.44% and year to date, the shares have picked up 91.12%. The
complimentary notes on FCSC can be downloaded in PDF format at:
http://www.aciassociation.com/FCSC.pdf
--
About ACI Association:
Active Charter Investors Association ("ACI Association")
produces regular sponsored and non-sponsored reports, articles,
stock market blogs, and popular investment newsletters covering
equities listed on NYSE and NASDAQ and micro-cap stocks. ACI
Association has two distinct and independent departments. One
department produces non-sponsored analyst certified content
generally in the form of press releases, articles and reports
covering equities listed on NYSE and NASDAQ and the other produces
sponsored content (in most cases not reviewed by a registered
analyst), which typically consists of compensated investment
newsletters, articles and reports covering listed stocks and
micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
ACI Association has not been compensated; directly or
indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the
"Sponsor"), provides necessary guidance in preparing the document
templates. The Reviewer has reviewed and revised the content, as
necessary, based on sound investment judgment and publicly
available information which is believed to be reliable. The
Reviewer and the Sponsor have not performed any independent
investigations or forensic audits to validate the information
herein. Unless otherwise noted, any content outside of this
document has no association with the Author, the Reviewer, or the
Sponsor (collectively referred to as the "Production Team") in any
way. The Production Team is compensated on a fixed monthly basis
and do not hold any positions of interest in any of the securities
mentioned herein. The information in this release has been
sourced from a third party data base.
NO WARRANTY
ACI Association, the Author, the Reviewer and the Sponsor
(collectively referred to as the "Publishers") are not responsible
for any error which may be occasioned at the time of printing of
this document or any error, mistake or shortcoming. No liability is
accepted by the Publishers whatsoever for any direct, indirect or
consequential loss arising from the use of this document. The
Publishers expressly disclaim any fiduciary responsibility or
liability for any consequences, financial or otherwise arising from
any reliance placed on the information in this document.
Additionally, the Publishers do not (1) guarantee the accuracy,
timeliness, completeness or correct sequencing of the information,
or (2) warrant any results from use of the information. The
included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither ACI Association nor any party affiliated
with us is a registered investment adviser or broker-dealer with
any agency or in any jurisdiction whatsoever. To download our
report(s), read our disclosures, or for more information, visit
http://www.aciassociation.com/.
RESTRICTIONS
ACI Association is not available to residents of Belarus, Cuba, Canada,
Iran, North Korea, Sudan, Syria
or Somalia.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE www.aciassociation.com